⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22028763 | 0.68 | — | — | |
| SCHEMBL1438699 | 0.64 | — | — | |
| SCHEMBL1962941 | 0.64 | — | — | |
| SCHEMBL609477 | 0.64 | — | — | |
| SCHEMBL5433994 | 0.60 | — | — | |
| SCHEMBL5434221 | 0.58 | — | — | |
| SCHEMBL8829825 | 0.56 | — | — | |
| SCHEMBL31612444 | 0.56 | — | — | |
| SCHEMBL3475574 | 0.56 | GSK3B (0.35) | — | |
| SCHEMBL6551950 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542609-A2 | METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS | Cytocure LLC (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040253235-A1 | Methods for up-regualting antigen expression of tumors | CYTOCURE LLC | 2004-12-16 | — | — | US | claimed |
| WO-2004019886-A2 | METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS | CYTOCURE LLC (US) | 2004-03-11 | — | — | WO | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1542609-B1 | Pharmaceutical compositions comprising Interferon beta for use in treating melanoma | CYTOCURE LLC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20120195855-A1 | METHODS FOR UP-REGULATING ANTIGEN EXPRESSION IN TUMORS | CYTOCURE LLC (US) | 2012-08-02 | — | — | US | disclosed |
| US-8071321-B2 | administering interferon-beta (IFN- beta) receptor agonist and tumor associated antigen to increase an immune response against the tumor cells | CYTOCURE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2283114-A2 | TREATMENT OF PLURIPOTENT CELLS | Centocor Ortho Biotech Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-6136974-A | Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments | ASTRAZENECA UK LIMITED (GB) | 2000-10-24 | — | — | US | disclosed |
| EP-0991653-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-04-12 | — | — | EP | disclosed |
| US-6046204-A | Pyrrolo[3,4-D] pyrimidinone derivatives and their use as medicaments | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-04-04 | — | — | US | disclosed |
| US-6028074-A | FOR TREATING ALLOGRAFT REJECTION | ASTRA PHARMACEUTICALS, LTD. (GB) | 2000-02-22 | — | — | US | disclosed |
| EP-0946562-A1 | PYRROLO 3,4-$i(D)]PYRIMIDINONE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Astra Pharmaceuticals Limited (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998054190-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998028301-A1 | PYRROLO[3,4-D]PYRIMIDINONE DERIVATIVES AND THEIR USE AS MEDICAMENTS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-07-02 | — | — | WO | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |